Circulating endothelial markers have the potential to serve as advanced diagnostic and prognostic tools for vascular events in diabetes, though routine clinical application requires further validation.
Answers are grounded in this paper and cite their sources.
These biomarkers should not yet guide routine diabetes vascular care; leaves open their diagnostic value pending prospective validation.
Endothelial dysfunction is a predisposing factor for vascular disease in diabetes, which contributes significantly to the mortality of diabetic patients. The currently utilized assessment methods of endothelial function/dysfunction in humans are associated with various limitations. Circulating endothelial-derived/associated markers have been proposed as potential alternatives for evaluation of the endothelium in condition of vascular disorders. These indicators include von Willebrand factor, soluble thrombomodulin, soluble E-selectin, asymmetric dimethylarginine, tissue plasminogen activator, endothelial microparticles, circulating endothelial cells and circulating endothelial progenitor cells. While tentative evidence is available for most of these biomarkers to serve as reliable sources of information, their usefulness for routine clinical applications has not yet been established. Thus, circulating endothelial markers are currently the subject of intense research interest and it is anticipated that as more information becomes available their improved quantification will provide a suitable diagnostic and prognostic tool for vascular events in diabetes and related diseases.
No takes yet. Share an insight, caveat, or question.
Abebe et al. (2010) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: